pooled CV from MR vs. IR [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2018-01-18 17:46 (1894 d 06:18 ago) – Posting: # 18216
Views: 3,777


❝ […] I found a cross-over study comparing pharmacokinetics of biperiden immediate release against extended release.

❝ Is it reasonable to assume the CVwithin of biperiden to be equal to the one on the study that I found?

Difficult to say. Can you give the reference?

❝ I mean, I think it will be smaller or equal at most, therefore if I assume it is the same for the sake of sample size calculation, I could be overestimating sample size, but I would not be sacrificing any statistical power, which is not statistically incorrect, right?

Maybe. Maybe not. Even if sampling times were properly chosen in the study you found, the variability of Cmax of the MR product might be lower than the one of the IR product – simply because MR profiles are “flatter”. What we get in a 2×2×2 crossover study is the pooled variability (from the unknown swR and swT). Given that, it might well be that the CVw of IR is higher than the one you extracted from the literature.
I suggest to perform a pilot study, a Two-Stage Design, or – if you want to go directly to the pivotal study – allow for a safety margin.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,555 posts in 4,724 threads, 1,606 registered users;
17 visitors (1 registered, 16 guests [including 8 identified bots]).
Forum time: 01:05 CEST (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz